Gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors of the gastrointestinal tract, are a relatively recently described entity. Most exhibit a mutated tyrosine kinase receptor gene and in some capacity are treated by tyrosine kinase inhibitors. GISTs can occur across the age spectrum but are more common in patients older than 40 years. They exhibit a wide range of clinical presentations and imaging characteristics. All patterns of enhancement on contrast enhanced computed tomography (CECT) can be seen with GISTs, including hypoenhancing, isoenhancing, and hyperenhancing tumors. They can be large or small, endoluminal or exophytic. Clinical presentations include asymptomatic patients, nonspecific symptoms, obstruction, and bleeding. Bleeding can take the form of slow, intraluminal GI bleeding or massive intraperitoneal bleeding secondary to rupture and can be seen regardless of the enhancement pattern. Some can cavitate, ulcerate, rupture or cause fistulae. The radiologist’s knowledge of the variety of combinations of presentations can narrow the differential diagnosis and ultimately lead to faster diagnosis and treatment.
GIST Focal small bowel lesions CT-enterography
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
No funding was received for this study.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
Statement of informed consent was not applicable since the manuscript does not contain any patient data.
Koumarianou A, Economopoulou P, Katsaounis P, et al. (2015) Gastrointestinal stromal tumors (GIST): a prospective analysis and an update on biomarkers and current treatment concepts. Biomark Cancer 7(Suppl 1):1–7CrossRefPubMedPubMedCentralGoogle Scholar
Levy AD, Remotti HE, Thompson WM, Sobin LH, Miettinen M (2003) Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 23(2):283–304CrossRefPubMedPubMedCentralGoogle Scholar
Ma GL, Murphy JD, Martinez ME, Sicklick JK (2015) Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomark Prevent 24(1):298–302CrossRefGoogle Scholar
Tiruman SH, Jagannathan JP, Krajewski KM, et al. (2013) Imatinib and beyond in gastrointestinal stromal tumors: a radiologist’s perspective. Am J Roentgenol 201:801–810CrossRefGoogle Scholar
Gold JS, Gönen M, Gutiérrez A, et al. (1045) Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009:10Google Scholar
DeMatteo RP, Lewis JJ, Leung D, et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231(1):51–58CrossRefPubMedPubMedCentralGoogle Scholar
Naguib SF, Zaghloul AS, El Marakby H (2008) Gastrointestinal stromal tumors (GIST) of the stomach: retrospective experience with surgical resection at the National Cancer Institute. J Egypt Natl Cancer Inst 20(1):80–89Google Scholar
Demetri GD, Benjamin RS, Blanke CD, et al. (2007) NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Cancer Netw 5(Suppl 2):S1–S29 (quiz S30)Google Scholar
Huang RX, Xiang P, Huang C (2014) Gastrointestinal stromal tumors: current translational research and management modalities. Eur Rev Med Pharmacol Sci 18:3076–3085PubMedPubMedCentralGoogle Scholar
Miettinen M, Sobin LH, Lasota J (2005) Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29(1):52–68CrossRefPubMedPubMedCentralGoogle Scholar
Linch M, Claus J, Benson C (2013) Update on imatinib for gastrointestinal stromal tumors: duration of treatment. Onco Targets Ther 6:1011–1023PubMedPubMedCentralGoogle Scholar
Therasse P, Arbuck SG, Eisenhauer EA (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedCentralGoogle Scholar
Shankar S, Dundamadappa SK, Karam AR, Stay RM, van Sonnenberg E (2009) Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy. Acta Radiol 50:837–844CrossRefPubMedPubMedCentralGoogle Scholar
Chen MY, Bechtold RE, Savage PD (2002) Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 179:1059–1062CrossRefGoogle Scholar
Chen YT, Sun HL, Luo JH, et al. (2014) Interventional digital subtraction angiography for small bowel gastrointestinal stromal tumors with bleeding. World J Gastroenterol 20(47):17955–17961PubMedPubMedCentralGoogle Scholar
Alessiani M, Gianola M, Rossi S, et al. (2014) Peritonitis secondary to spontaneous perforation of a primary gastrointestinal stromal tumour of the small intestine. Int J Surg Case Rep 6:58–62CrossRefPubMedCentralGoogle Scholar